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A B S T R A C TObjectives: Health outcomes instruments assess diverse health con-
cepts. Although item-level concepts are considered fundamental
elements, the field lacks structures for evaluating and organizing
them for decision making. This article proposes a grammar using item
stems, response options, and recall periods to systematically identify
item-level concepts. The grammar uses ‘‘core concept,’’ ‘‘evaluative
component,’’ and ‘‘recall period’’ as intuitive terms for communicating
with stakeholders. Better characterization of concepts is necessary for
classifying instrument content and linking it to treatment benefit.
Methods: Items in 2 generic and 21 disease-specific instruments were
evaluated to develop and illustrate the use of the grammar. Concepts
were assigned International Classification of Functioning, Disability
and Health codes for exploring the value that the grammar and a
classification system add to the understanding of content across
instruments. Results: The 23 instruments include many core con-
cepts; emotional function is the only concept assessed in all instru-
ments. Concepts in disease-specific instruments show obvioussee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.008
u.edu.
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SA.patterns; for example, arthritis instruments focus on physical func-
tion. The majority of instruments used the same response options
across all items, with five-point scales being the most common. Most
instruments used one recall period for all items. Shorter recall periods
were used for conditions associated with ‘‘flares,’’ such as chronic
obstructive pulmonary disease and ‘‘skin disease.’’ Every diagnosis,
however, showed variation across instruments in the recall
period used. Conclusions: This analysis indicates the proposed
grammar’s potential for discerning the conceptual content within
and between health outcomes instruments and illustrates its value
for improving communication between stakeholders and for making
decisions related to treatment benefit.
Keywords: Core concepts, International Classification of Functioning,
Disability, and Health (ICF), patient-reported outcomes, taxonomy.
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Instruments that measure health from an individual’s perspec-
tive assess a wide range of concepts of health and well-being and
are used for evaluating treatment benefit throughout the world
[1–4]. The development of these instruments can be traced to
generic measures of health that emerged in the 1970s [5–8] and
were based on the 1948 World Health Organization’s definition of
health as ‘‘physical, mental, and social well-being’’ [9]. This
tripartite classification was expanded by Ware [10] to include
disease, personal functioning, psychological distress/well-being,
general health perceptions, and social/role functioning. Subse-
quently, Wilson and Cleary [11] modified the Ware model to
include a medical focus and external factors. Patrick and Chiang
[12] expanded this model to include more detail on both the
health concepts and factors due to the environment and personal
and lifestyle factors. These conceptual models have been used asthe basis for the development of numerous generic and disease-
specific instruments ranging in complexity from multi-item
scales that assess a single concept, for example, depression, to
scales that measure multiple concepts by using multiple scales
that may, or may not, be aggregated to form an overall outcome
measure [13–15]. In the past decade, generic instruments have
become increasingly widely used to measure health status, for
example, in population surveys by the Medical Care Expenditure
Survey and the Medicare Health Outcomes Survey [16,17]. During
the same time, specific measures have become routinely used to
assess health and treatment outcomes in clinical research stud-
ies including those used for new drug development [18].
Approximately one third of all new drugs approved by the U.S.
Food and Drug Administration in the period 1997 to 2003 and one
fourth in the period 2006 to 2010 included labeling claims based
on at least one patient-reported outcome (PRO) instrument
[18,19]. This information was used in the process of generatingSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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pean Medicines Agency Reflection Paper [1,2]. The positions put
forth in these regulatory documents are now being expanded to
include information reported by clinicians and by patients’
observers. Together these reported assessments are referred to
as clinical outcomes assessments (COAs) [20].
As a result of the growing importance of obtaining individu-
als’ input into health care decision making, the number and
diversity of instruments have increased exponentially in the past
30 years. Common features, however, exist across instruments.
At the item level, COAs include core concepts that are considered
to be fundamental elements of the broader concepts that may be
represented by multi-item scales.
Together with the core concept, other aspects of item wording
are also important to fully understand item content, namely, the
recall period, the response option, and the verb-adverb of the
question (‘‘how often are,’’ ‘‘how troubled by,’’ ‘‘how severe are’’);
these elements, which comprise the ‘‘grammar’’ of COAs, convey
the precise way that the core concept can be systematically
evaluated within a given item. Better characterization of the
choice set, not only for the core concepts but also for the other
aspects of the grammar, would lead to a more complete classi-
fication of the conceptual content of an item in a COA and how it
measures a specific treatment benefit.
Two recent initiatives that aim to provide a structure for
classifying core concepts within COAs are the Patient Reported
Outcomes Measurement Information System and the Interna-
tional Classification of Functioning, Disability, and Health (ICF)
[21,22]. Both of these add lower-level concepts, for example,
activities of daily living and instrumental activities of daily living,
to the physical concept. Because both the Patient Reported Out-
comes Measurement Information System and the ICF were
developed for uses broader than determining treatment efficacy,
each lacks a structure that relates a health concept to its role in
evaluating treatment outcome, for example, whether or not a
concept is appropriate for making an explicit statement of treat-
ment benefit as might appear in a label claim.
To aid the understanding of COA concepts and their contri-
bution to the drug-approval process and decision making more
broadly, Erickson et al. [23] proposed the PRO Concept Taxonomy.
This hierarchical structure has four levels: family, compound,
singular, and low-level singular concepts. While concepts as well
as their names and definitions have yet to be specified, family-
level concepts can be thought of as corresponding to those in the
1948 World Health Organization definition and its subsequent
modifications. Concepts at each level correspond to the impor-
tance placed on them by those who are directly involved with the
patient’s response to treatment. Some item-level concepts, such
as shampooing hair, are unlikely to be of sufficient importance
for labeling and would be considered low-level singular concepts.
Other item-level concepts, such as pain severity, may be singular
concepts if they can be used for claiming treatment benefit.
Multi-item scales form singular or higher-level concepts. A
hierarchical structure, such as that in the PRO Concept Taxon-
omy, allows investigators to identify patient-relevant concepts
that are appropriate for the intended claim of treatment benefit
at the time of trial design, thus increasing the likelihood that the
trial results will support the desired labeling.
While other taxonomies have been proposed for use with PRO
measures [24–26], these efforts focus on practical characteristics
of instruments, for example, respondent burden. These systems
are similar to the PRO Instrument Hierarchy that was developed
as a companion structure to the PRO Concept Taxonomy. Struc-
tures that categorize instruments on the basis of their measure-
ment features, rather than conceptual content, are also
important tools that can improve communication among
researchers, sponsors, and other consumers of COA information.There is certainly an awareness of the importance of not only
the core concepts but also other aspects of the grammar of COA
items [27,28]. The final FDA PRO guidance devotes specific atten-
tion to recall periods and response options. There has been less
effort to classify these aspects, however, than there has been to
organize the concept taxonomies. Nor has there been much effort
to analyze the impact of differences in recall and response formats
on the measurement and interpretation of otherwise similar core
concepts. Whether or not variations in these other components of
the grammar will make significant differences in the overall
content and psychometrics of an item is an empirical, case-by-
case, question, but it cannot be assumed that they will not matter.
Better delineation of the structure and usage of this grammar
would be a useful step in addressing these considerations. As this
brief review indicates, the key for having meaningful discussions
about the use and interpretation of COAs is to have a common
language for understanding an instrument’s content and potential
for decision making. This language needs to be compatible with
concepts measured by existing measures and also with those in
instruments being developed now and in the future.
This article evaluates the syntax and language of items to
develop a descriptive, item-level, grammar of COAs that can guide
users in identifying item-level concepts and understanding each
concept’s role in evaluating and making a statement of treatment
benefit. For comparison, analysis, and communication, core con-
cepts are best understood as part of cohesive concept taxonomy.
In addition to introducing the grammar, this article suggests the
value of using both the grammar and taxonomy for evaluating
instrument selection within the context of a given application.
Similarities of concepts within levels of the taxonomy indicate
confirmatory information; differences suggest disparate concepts
that need further investigation. The grammar is designed to be
applicable to existing and new and generic and disease-specific
instruments. Items in a sample of PRO instruments are compared
and contrasted by using the grammar to identify similarities and
differences in the core concepts across instruments. The ICF was
used to explore the value that the proposed grammar adds to the
evaluation and classification of the conceptual content of various
instruments. The ICF was selected because it has 1) a well-defined
hierarchical structure similar to that in the PRO Concept Taxon-
omy; 2) clearly stated concept definitions that enable the match-
ing of core concepts in items in the sampled instruments to levels
in the hierarchy; and 3) a coding system that indicates the
location of the concept in the taxonomy, in terms of its con-
ceptual content and its potential role in decision making. The
longer the ICF code, the more detailed the concept, the narrower
the concept, and the more restricted the concept’s role in decision
making. Thus, a subtext is to evaluate the ICF’s potential for
populating a PRO Concept Taxonomy as a step toward developing
a standardized terminology for improving communication among
the various stakeholders involved in evaluating treatment benefit.Methods
To systematically evaluate the conceptual content of items in COA
instruments, as well as to provide considerations for new instru-
ment development, we propose a grammar based on the item-
stem wording, recall period, and response option. This grammar
takes into account the role that modifying phrases play in under-
standing the item’s core concept. Table 1 identifies the primary
components in this descriptive tool and gives a brief definition and
statement of purpose for each. In addition, grammar components
are expressed in terms chosen to make them more intuitive to
those unfamiliar with terms used primarily by COA researchers.
All items have three components—core concept, evaluation, and
recall period—with the first two each having a subcomponent.
Table 1 – Tools in the grammar of clinical outcomes assessment instruments.
Grammar
component
Item section Definition Purpose
Core concept—Event Item stem A facet of health, function, or
well-being that is evaluated by
or for the patient. This may be
expressed as a verb, possibly
with an object
Expresses the core concept being measured
Core concept—Modifier Item stem A phrase that connects the event
to the context of
measurement, which is
usually a disease or specific
health condition, but may be
another causal or conditioning
factor. The context may be
stated in either the
instructions to the respondent
or the item stem or both
Improves the validity of the response by
focusing the respondent’s attention on the
health-related feature or other specific
context of the event
Evaluation—Aspect Item stem and/or
response option
An expression for the nature of
the impact that the event, as
modified, has on the patient or
respondent’s life
Specifies the intensity, frequency, severity, or
degree of certainty with which the
respondent interprets the event
Evaluation—Rating Response options Number and type of rating
options available to the
respondent for evaluating the
impact of a given event, as
modified
Designates the variation in an evaluation that
is considered important to the concept
being measured. More response choices
usually indicate a more nuanced
evaluation of the event
Recall period Item stem and/or
response option
The length of time or time period
that the event and evaluation
are relevant for the purpose of
measurement
Indicates the time interval important for
identifying a change in health outcome
that is meaningful for decision making,
e.g., in the drug-approval process
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 5 4 – 5 6 3556Each item stem contains a core concept that fits within one, and
only one, family-level concept and contains the facet of health,
function, or well-being that is evaluated by or for the patient.
Because this is usually phrased as a statement about what is
happening to the patient, we refer to this as an event. An event
may be conveyed by using a linking or sensory verb, for example,
am, are, have, feel, or seem, or as an action, for example, drive,
walk, or run. It may include an object as well as the verb, for
example, ‘‘changing basic body position.’’ A core concept may also
have a modifying phrase—a modifier—that relates the event to the
disease context or to a specific causal factor, or imposes a condition
on the event context; the latter does not necessarily apply attribution.
This modifying phrase may be seen in the item stem itself but may
also be in the instructions to the respondent. By placing the core
concept/event within a specific context, the modifier allows for a
more targeted, and more clearly interpreted, response. However, it
also means that itemswith the same core concept may elicit different
responses in different contexts. For example, a core concept such as
being ‘‘scared or worried’’ could elicit quite different responses
depending on whether the context is ‘‘about your lung problems’’ as
compared to ‘‘about having family support when I need it.’’
Each item also has an evaluation component that expresses
the aspect and rating of the event. This component may appear in
either the stem or the response options or both, and indicates the
aspect of the core concept that is being measured, for example,
frequency (how often y?), intensity, severity, bother, and so on,
as well as the scale on which it is being rated. The term aspect is
used here as an expression for the nature of the impact that the
event, as modified, has on the patient or respondent’s life. The
specification of aspect is important, in that the interpretation of a
core concept may vary significantly depending on the aspect
being evaluated, such as frequency versus severity ofbreathlessness [29,30]. Similarly, in the rating part of this com-
ponent, the wording and range of the response options may have
important effects on the sensitivity of a given item, including
floor and ceiling effects. Because response ranges can vary from
yes-no options (e.g., the St. George’s Respiratory Questionnaire
for chronic obstructive pulmonary disease [COPD]) to the visual
analogue scale or 11-point ranges (e.g., the OAKHQOL for arthri-
tis), there is a considerable margin for variation here [31,32].
The recall period, already a familiar item component, indi-
cates the time period of the event that is relevant for the purpose
of measurement, for example, determining treatment benefit or
evaluating population health [33]. Recall period is sometimes
expressed as an implicit ‘‘now’’ or as ‘‘at this point in time.’’
Table 2 shows the 2 generic and 21 disease-specific instru-
ments selected for examining the grammar components. The
disease areas were chosen to reflect both common and less
common disease areas; the specific instruments were chosen as
being commonly used, or otherwise significant, instruments in
those areas. Item stems, response options, and recall periods for
these instruments were entered into a spreadsheet and evaluated
to determine the core concept, including the event, modifier,
evaluation aspect and rating, and recall period. For some instru-
ments, we used information that was stated in the instructions
to the respondent, when such information was not stated in the
individual items. This resulted in 618 items available for analysis.
Table 3 presents examples of core concepts from these PRO
instruments. In Chronic Respiratory Questionnaire item 12, the
core concept is considered to be control or mastery; the phrase
‘‘of your breathing problems’’ acts as a modifier. The event of
breathless assessed in London Chest Activities of Daily Living
Scale item 1 is considered to be dependent on performing the
self-care activity of drying oneself, a modifier. This item
Table 2 – Disease or generic content and initials for
PRO instruments used in this analysis.
Context Initials of PRO instruments
Arthritis AIMS2, DASH, HAQ, KOOS, OAKHQOL
COPD CRQ, EXACT, LCADL, PFSS, SGRQ
Fibromyalgia FIQ
Head & neck
cancer
FACT-H&N, HNQOL, QOL-RTI, VHI, XQ
Skin disease DLQI-10, PDI-15, PLSI, PSORIQoL, Skindex-
29
Generic EQ-5D, SF-12
AIMS2, Arthritis Impact Measurement Scales 2 [34]; CRQ, Chronic
Respiratory Questionnaire [35]; DASH, Disabilities of the Arm,
Shoulder, and Hand [36]; DLQI-10, Dermatology Life Quality Index
10 [37]; EQ-5D, EuroQol five-dimensional [38]; EXACT, EXAcerba-
tions of Chronic Obstructive Pulmonary Disease [39]; FACT-H&N,
Functional Assessment of Cancer for Patients with Head and Neck
Cancer [40]; FIQ, Fibromyalgia Impact Questionnaire [41]; HAQ,
Health Assessment Questionnaire [42]; HNQOL, Head and Neck
Quality of Life Instrument [43]; KOOS, Knee Osteoarthritis Out-
come Scale [44]; LCADL, London Chest Activities of Daily Living
Scale [45]; OAKHQOL, Osteoarthritis Knee and Hip Quality of Life
[32]; PDI, Psoriasis Disability Index 15 [46]; PFSS, Pulmonary
Functional Status Scale [47]; PLSI, Psoriasis Life Stress Inventory
[48]; PRO, patient-reported outcome; PSORIQoL, Psoriasis Index of
Quality of Life [49]; QOL-RTI, Quality of Life-Radiation Therapy
Instrument [50]; SF-12, SF-12 Health Survey [51]; SGRQ, St. George’s
Respiratory Questionnaire [31]; Skindex-29, Skindex-29 [52]; VHI,
Voice Handicap Index [53]; XQ, Xerostoma Questionnaire [54].
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concept being assessed. Several items, for example, the Func-
tional Assessment of Cancer for Patients with Head and Neck
Cancer GE4 item, illustrate that not all items have a modifier.
The core concept in each itemwas assigned a classification code
from at least one of five primary ‘‘components’’ in the ICF. Three
components classify aspects of Functioning and Disability in terms
of Body Functions (b), Structures (s), and Activities and Participation
(d). Two other components are the Environmental Factors (e) and
the Personal Factors; this latter chapter has yet to be fully incorpo-
rated into the ICF. Each component is subdivided into ‘‘chapters’’
(e.g., chapter b1 is ‘‘Mental Functions’’), and then further into
specific four- to –five-digit categories (e.g., b110 is ‘‘Consciousness
Functions’’). Table 4 illustrates the hierarchical structure used in the
ICF for Mobility (d4), with detailed information for the category Fine
Hand Use (d440). Other chapters have the same structure.
In the ICF structure, the most specific concepts are repre-
sented with four-digit codes and can be considered to correspond
to low-level singular concepts in the PRO Concept Taxonomy.
Shorter codes represent increasingly more composite concepts,
analogous to the singular and compound concepts. In general,
the ICF is quite detailed for physical functioning but relatively
weak on emotional content.
Each category is accompanied by a brief description of the
concept as illustrated at the bottom of Table 4. These descriptions
were used for assigning ICF codes to the core concepts in our
sample. Some items were assigned two codes, usually one from
Functioning and Disability and the other from the Environmental
Factors section, if no single code seemed to completely represent
the core concept.
For this analysis, the percentage of each instrument’s items at
each two-digit ICF level (e.g., d4 in Table 4) was calculated, along
with the average and high and low percentages across the five
instruments within a disease area. Recall periods for all items
were grouped into five categories (now, last few days, past week,
past 2 weeks, past month). When an instrument included more
than one recall period, the predominant period was used. The
number of response options for each item was identified, with
the predominant number being compared across instruments.Table 3 – Examples of items, disease context, and comp
using the grammar of health-related quality of life.
Instrument,
item number
Item D
CRQ, item 12 How often did you feel you had complete
control of your breathing problems?
C
PDI-15, item 3 How much of the time have you had to change
or wash your clothes?
P
AIMS2, item 40 How often did you have pain in two or more
joints at the same time
A
EXACT, item 14 How scared or worried were you about your
lung problems today?
C
LCADL, item 1 How breathless have you been whilst.. drying C
FACT-H&N,
item GE4
I feel nervous H
FACT-H&N,
item GP3
Because of my physical condition, I have
trouble meeting the needs of my family.
H
AIMS2, item 34 Did you feel that your family or friends would
be around if you needed assistance?
A
AIMS2, Arthritis Impact Measurement Scales 2; CA, cancer; COPD, c
Questionnaire; EXACT, EXAcerbations of Chronic Obstructive Pulmonary
with Head and Neck Cancer; LCADL, London Chest Activities of Daily LiThe evaluation-aspect of the event being queried is coded for each
item; common responses were frequency, severity, difficulty, and
extent; more than 20 different response types were identified.
The percentage of each instrument’s items with each evaluation-
aspect was calculated.onents of core concepts from existing instruments
isease
context
Core concept—Event Core
concept—Modifier
OPD Control, mastery Of your breathing
problems
soriasis Dressing, change clothes None
rthritis Pain In two or more joints
at the same time
OPD Scared or worried About your lung
problems
OPD Breathless Whilst drying
ead and
neck
CA
Nervous None
ead and
neck
CA
Meeting the needs of my
family
Because of my
physical condition
rthritis Family or friends would be
around - social support
If you needed
assistance
hronic obstructive pulmonary disease; CRQ, Chronic Respiratory
Disease; FACT-H&N, Functional Assessment of Cancer for Patients
ving Scale; PDI-15, Psoriasis Disability Index 15.
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As shown in Table 5, generic and disease-specific instruments
included in this analysis include a range of core concepts. The
Emotional Functions category, which is in 18 of the 23 instru-
ments, is included in each of the disease-specific categories as
well as in generic instruments. Disease-specific instruments
show some obvious patterns; for example, concepts of voice,
communication, and swallowing are assessed only in the head
and neck cancer instruments; similarly, the core concept of skin
sensitivity appears only in instruments specific to skin diseases.
As might be expected, the core concepts in the arthritis instru-
ments tend to cluster in the Activity and Participation section of
the ICF. The use of the Activity and Participation component, as
well as mental functions (b1), however, varies quite a bit within
other disease areas and is a point for consideration in comparing
and evaluating instruments in those areas.
Figure 1A shows the percentage of core concepts included in
the five arthritis-specific instruments according to the average-
high-low analysis. Mobility was most common, comprising an
average of 39% of the items across the five instruments, and was
included in all five instruments here. Self-care activity was the
next most frequently occurring concept, approximately 12% of
items overall, and was also included in all five instruments. Four
other ICF two-digit areas comprised at least 5% of all items, but
none was included in all five instruments.
Figure 1B shows the same analysis for the COPD-specific
instruments. Sensory functions/pain (50% overall) and mental/
emotional (20% overall) were the two most common concept
areas used and were included in all these COPD instruments.Table 4 – ICF codes and hierarchical structure
within the Mobility chapter (d4).
ICF code Mobility chapter category heading
d410-d429 Changing and maintaining body position
d430-d449 Carrying, moving, and handling objects
d430 Lifting and carrying objects (d4300-d4309)
d435 Moving objects with lower extremities
(d4300-d4309)
d440 Fine hand use (d4400-d4409)
d4400 Picking up
d4401 Grasping
d4402 Manipulating
d4403 Releasing
d4408 Fine hand use, other specified
d4408 Fine hand use, other specified
d445 Hand and arm use (d4450-d4459)
d449 Carrying, moving, and handling objects,
other specified and unspecified (d4450-
d4459)
d450-d469 Walking and moving
d440 description
of concept
Fine hand use: Performing the coordinated
actions of handling objects, picking up,
manipulating, and releasing them using
one’s hand, fingers, and thumb, such as
required to lift coins off a table or turn a
dial or knob. Inclusions: picking up,
grasping, manipulating, and releasing.
Exclusion: lifting and carrying objects
(d430)
ICF, International Classification of Functioning, Disability, and
Health.Mobility and domestic life each comprised at least 5% overall but
were not included in each of the five COPD instruments.
The most common core concept in the five head and neck
cancer–specific instruments (Fig. 1C) was the voice and speech
functions category, occurring in approximately 30% of the items.
This category was included in all five instruments. Mental/emo-
tional, sensory functions/pain, and digestive/metabolic/endo-
crine functions also achieved at least 5% overall but were not
included in all these head and neck cancer instruments.
Mental/emotional and community/social/civic life were the
most common core concepts, each more than 20% overall, in the
five skin disease–specific instruments (Fig. 1D). Interpersonal
interactions and self-care were also included in all five instru-
ments. Three other areas also comprised at least 5% of the items,
overall.
Table 6 shows predominant response options in the 20
disease-specific instruments in the four diagnostic categories
with multiple instruments. The majority of the instruments
(70%) used the same number of response options across all their
items. Five-point scales were most commonly used (eight instru-
ments), but overall six different numbers of response options
were used, ranging from 2-point (yes/no, true/false) to 11-point
(0–10 range) scales. Every disease area, however, showed varia-
tion across instruments in the type of response scale used. The
Fibromyalgia Impact Questionnaire used a four-point Likert-type
response and scaling approach for all but 2 of the 13 items.
Information on recall period is shown in Table 7. Most instru-
ments (85%) used a single recall period for all their items. ‘‘The
past week’’ was the most commonly used, particularly in arthritis
and head and neck cancer. ‘‘Now’’ or ‘‘past month’’ or ‘‘past 4
weeks’’ were also very common. Every disease area, however,
showed variation across instruments in the recall period used.
Figure 2A,D presents the average-high-low percentages for the
evaluation-aspect grammar components of items in the five instru-
ments in the four disease areas. For the arthritis instruments,
questions about difficulty with activities were the most common
across instruments (53% overall), with impact, severity, and
frequency each comprising 7% to 15% overall. The most common
evaluation aspects used in COPD instruments were extent (39%
overall) and frequency (26% overall), with severity, difficulty,
and yes/no responses comprising 6% to 17% of all responses.
Similarly, extent (37% overall) and frequency (28% overall)
were the most commonly used in head and neck cancer instru-
ments; bother and difficulty were also used (9%–17%). For the
psoriasis/skin disease instruments, extent (38% overall) was
most common; stress, frequency, and yes/no responses were the
only other types used; in this disease area, four out of five
instruments used only one aspect type.
Other aspect types not noted above but found across instru-
ments and disease areas included satisfaction, problem, embar-
rassed, wellness, limitation, troubled, agreement, depressed,
global rating of health, perception, and worry. In this grammar
component as well, instruments take quite different approaches
to evaluation aspects within disease areas.Discussion
This article proposes a descriptive, rather than a prescriptive,
grammar for evaluating conceptual content in COA instruments.
At the item level, concepts consist of three components: a core
concept consisting of an event, which may have a modifying
clause (a modifier); an evaluation (both aspect and rating); and a
recall period. The evaluation and recall period components largely
represent the nature of the response to the core concept being
evaluated. Together, the three components identify an item-level
concept for use in evaluating treatment benefit.
Table 5 – Core concepts included in instruments, arranged by ICF chapter codes and type of instrument.
Main ICF
component
Core concept (chapter) ICF chapter
code
Disease area (number of instruments)
Arthritis
(5)
Head & neck
CA (5)
COPD
(5)
Fibromyalgia
(1)
Skin
disease (5)
Generic
(2)
Total
(23)
Number of instruments that include core concept
Body Functions (b) Mental functions b1 3 4 3 1 5 2 18
Sensory functions and pain b2 4 4 0 1 1 2 12
Voice/speech b3 0 5 0 0 0 0 5
Respiratory function b4 0 3 1 1 0 0 5
Digestive, metabolic, and
endocrine functions
b5 0 5 0 0 0 0 5
Intimacy b6 1 1 1 0 0 0 3
Neuromusculoskeletal function b7 2 1 0 1 0 0 4
Skin and related structure b8 0 0 0 0 3 0 3
Body Structures (s) Head and neck shape s7 0 1 0 0 0 0 1
Activities and
Participation (d)
Tasks d2 1 0 1 0 0 0 2
Communication d3 0 1 0 0 0 0 1
Mobility d4 5 0 3 1 0 2 11
Self-care d5 5 1 2 0 4 1 12
Domestic life d6 4 0 2 1 0 2 9
Interpersonal interactions d7 2 1 0 0 4 0 3
Major life areas d8 2 3 0 1 0 0 6
Environmental
Factors (e)
Personal consumption e1 1 2 0 0 0 0 3
Family e3 0 2 0 0 0 0 2
Social support e4 1 1 0 0 0 0 2
NA Global No ICF code 1 2 1 0 0 1 4
ICF, International Classification of Functioning, Disability, and Health; NA, not applicable/available.
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Fig. 1 – The average percentage of items within an instrument in given two-digit International Classification of Functioning,
Disability, and Health (ICF) categories, as well as the high and low percentages, across the five instruments in the disease
category. (A) Percentage of items by ICF category for five arthritis instruments. Other includes ICF chapters b3, b4, b5, b6, d3,
d8, d9, e1, e3, e4, and globals (see Table 5). (B) Percentage of items by ICF category for five COPD instruments. Other includes
ICF chapters b6, d2, d9, and globals (see Table 5). (C) Percentage of items by ICF category for five head and neck cancer
instruments. Other includes ICF chapters b4, b6, b7, d3, d5, d7, d8, d9, s7, e1, e3, and e4 (see Table 5). (D) Percentage of items
by ICF category for five psoriasis/skin disease instruments. Ave, average; COPD, chronic obstructive pulmonary disease;
endo, endocrine; fctns, functions; metab, metabolic; pct, percentage.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 5 4 – 5 6 3560Development of a descriptive grammar, rather than specific
rules, for understanding the conceptual content of an item seems
to be an appropriate approach for identifying item content. As in
everyday speech, the grammar may be important forTable 6 – Predominant number of response options, by d
Number of response options Arthritis
2 patients S
4 patients HAQ
5 patients AIMS2, DASH, KOOS E
6 patients P
7 patients C
11 patients OAKHQOL
AIMS2, Arthritis Impact Measurement Scales 2; COPD, chronic obstructive
Disabilities of the Arm, Shoulder, and Hand; DLQI-10, Dermatology Li
Pulmonary Disease; FACT-H&N, Functional Assessment of Cancer for
Questionnaire; HNQOL, Head and Neck Quality of Life Instrument; KOOS
of Daily Living Scale; OAKHQOL, Osteoarthritis Knee and Hip Quality of L
Status Scale; PLSI, Psoriasis Life Stress Inventory; PSORIQoL, Psoriasis I
Instrument; SGRQ, St. George’s Respiratory Questionnaire; Skindex-29, Sk
 Used a different number of response options in a minority of items.understanding an item’s content and patient’s response
within the context of treatment benefit; this, in turn, may affect
content validity and inform comparisons of results across
instruments.isease and instrument.
COPD Head & neck cancer Psoriasis
GRQ PSORIQoL
DLQI-10, PLSI
XACT FACT H&N, HNQOL, VHI Skindex-29
FSS, LCADL
RQ PDI-15
QOT-RTI, XQ
pulmonary disease; CRQ, Chronic Respiratory Questionnaire; DASH,
fe Quality Index 10; EXACT, EXAcerbations of Chronic Obstructive
Patients with Head and Neck Cancer; HAQ, Health Assessment
, Knee Osteoarthritis Outcome Scale; LCADL, London Chest Activities
ife; PDI-15, Psoriasis Disability Index 15; PFSS, Pulmonary Functional
ndex of Quality of Life; QOL-RTI, Quality of Life-Radiation Therapy
index-29; VHI, Voice Handicap Index; XQ, Xerostoma Questionnaire.
Table 7 – Predominant recall period used by disease and instrument
Recall period Arthritis COPD Head & neck cancer Psoriasis
Now/implied present EXACT, PFSS, SGRQ PSORIQoL
Last few days LCADL
Past week DASH, HAQ, KOOS FACT H&N, QOL-RTI, VHI, XQ DLQI-10
Past 2 wk CRQ
Past 4 wk or month AIMS2, OAKHQOL HNQOL PDI-15, PLSI, Skindex-29
AIMS2, Arthritis Impact Measurement Scales 2; COPD, chronic obstructive pulmonary disease; CRQ, Chronic Respiratory Questionnaire; DASH,
Disabilities of the Arm, Shoulder, and Hand; DLQI-10, Dermatology Life Quality Index 10; EXACT, EXAcerbations of Chronic Obstructive
Pulmonary Disease; FACT-H&N, Functional Assessment of Cancer for Patients with Head and Neck Cancer; HAQ, Health Assessment
Questionnaire; HNQOL, Head and Neck Quality of Life Instrument; KOOS, Knee Osteoarthritis Outcome Scale; LCADL, London Chest Activities
of Daily Living Scale; OAKHQOL, Osteoarthritis Knee and Hip Quality of Life; PDI-15, Psoriasis Disability Index 15; PFSS, Pulmonary Functional
Status Scale; PLSI, Psoriasis Life Stress Inventory; PSORIQoL, Psoriasis Index of Quality of Life; QOL-RTI, Quality of Life-Radiation Therapy
Instrument; SGRQ, St. George’s Respiratory Questionnaire; Skindex-29, Skindex-29; VHI, Voice Handicap Index; XQ, Xerostoma Questionnaire.
 Used a different recall period in a minority of items.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 5 4 – 5 6 3 561For comparison, analysis, and communication, however, core
concepts are best understood if there is a cohesive taxonomy that
is associated with the proposed grammar. The ICF is one such
candidate but, while quite detailed for physical functioning, is
relatively weak on emotional content. In addition, the ICF has yetA
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Fig. 2 – Average percentage of items within an instrument with
being evaluated), as well as the high and low percentages, acros
of items by evaluation aspect for five arthritis instruments. Ot
limitation, worry, and many others. (B) Percentage of items by e
aspects such as satisfaction, distance, problem, and duration. (C
neck cancer instruments. Other includes aspects such as satis
Percentage of items by evaluation aspect for five psoriasis/skin d
pulmonary disease; pct, percentage.to incorporate a diversity of formats for response options and
recall periods into its structure. These limitations preclude its
adoption for a complete PRO Concept Taxonomy that needs to
include the full range of core concepts used in COAs as well as
the response options and recall periods.B
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given evaluation aspects (i.e., the nature of the core concept
s the five instruments in the disease category. (A) Percentage
her includes aspects such as satisfaction, wellness, extent,
valuation aspect for five COPD instruments. Other includes
) Percentage of items by evaluation aspect for five head and
faction, embarrassed, perception, severity, and yes/no. (D)
isease instruments. Ave, average; COPD, chronic obstructive
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 5 4 – 5 6 3562In examining item content for the 21 disease-specific instru-
ments analyzed, we found expected differences across diseases
in terms of events, evaluation components, and duration as well
as similarities within diseases. The analysis also indicated con-
siderable variation within diseases in all structural parts. Thus,
even if the events are similar across instruments within a
disease, the variation in how those concepts are combined with
evaluation and duration components could result in different
concepts related to treatment benefit. For example, a COA
measure with a core concept of pain and a recall period framed
in terms of hours will generally be more meaningful for an acute
migraine treatment than for one for a chronic condition such as
arthritis. While the findings presented here focus on disease-
specific instruments, the grammar was also found to be appli-
cable to generic instruments, adding support for validity and
generalizability of the proposed grammar. The validity informa-
tion will be enhanced with the evaluation of more instruments.
The ability of the grammar to fit with the ICF categories is
another indication of its validity. Another planned approach to
validation is to compare the item content identified using the
grammar with that using the linking rules developed for use with
the ICF [55–57].
In addition to introducing the grammar and taxonomy for
evaluating the conceptual content in COA instruments, this
analysis suggests their value for use in evaluating instrument
selection within the context of a given application. For example,
these tools can provide standards for validating concepts
included in instruments being considered for use, for example,
in the drug-approval process; these standards apply to both
newly developed and extant instruments. Similarities of concepts
at all levels can be interpreted as confirmatory information.
Observed differences, for example, inclusion of a new
singular or compound concept, would likely require exploratory
analyses to determine whether these differences were due to
problems in the instrument development process, such as mis-
specification of the intended patient population, or due to
changes in the nature of the disease impact due to technological
advances.
Toward the goal of improving communication between
researchers, sponsors, and regulators, all of whom bring their
own professional languages to the discussion, we have proposed
a simple grammar for evaluating and understanding item con-
tent. The grammar is designed to be used across COA instru-
ments regardless of their theoretical foundations. This
systematic approach to evaluating and classifying conceptual
concepts in COA instruments aims to link patients’ assessments
of treatment benefit directly to health decision making whether
at the clinical practice level or the macro-level policy level.
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